Trial of Anifrolumab in Active Systemic Lupus Erythematosus

F. Morand, Eric; Furie, Richard; Tanaka, Yoshiya; N Bruce, Ian; Askanase, Anca; Richez, Christophe; Bae, Sang‐Cheol; Z. Brohawn, Philip; Pineda, Lilia; Berglind, Anna; Tummala, Raj

doi:10.1056/nejmoa1912196

Public

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Published in New England Journal of Medicine • Dec 18, 2019

Authors:

Eric F. Morand

Richard Furie

Yoshiya Tanaka

Abstract

BACKGROUND: Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end po...

Subject

Medicine

Monoclonal antibody

Lupus erythematosus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!